Health Care·Biotechnology·$24.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.76 | N/A | -10.27% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $3.76 | N/A | -10.27% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management conveyed a cautious outlook, highlighting the need to navigate ongoing challenges. They remain focused on future opportunities.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term growth despite current hurdles.
The earnings report indicates that United Therapeutics faced challenges this quarter, leading to a miss on EPS expectations. The stock reacted negatively, dropping 6.59%, likely due to investor concerns about the company's current performance and lack of guidance for the future.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MARATHON PETE CORP
Apr 30, 2018